8:00 - 9:30 A.M.  Breakfast and Registration (Main Lounge)
8:30 - 9:30 A.M.  Posters Set Up (Main Lounge)
9:30 A.M. - 4:30 P.M.  Poster Session (Main Lounge)
9:30 - 11:00 A.M.  All Authors Present
11:00 - 11:05 A.M.  Welcome and Introduction (Multi-Purpose Room A&B)

Steven K. Libutti, MD, FACS
Director
Rutgers Cancer Institute of New Jersey

11:05 A.M. - 12:00 P.M.  Keynote Address (Multi-Purpose Room A&B)

“Stem Cells: Coping with Stress and Memories”
Elaine Fuchs, Ph.D.
Rebecca C. Lancefield Professor of Mammalian Cell Biology and Development
Rockefeller University

12:00 - 1:00 P.M.  Lunch (Food Court)
1:00 - 4:00 P.M.  Focus Session A (Multi-Purpose Room A)
1:00 – 2:00 P.M.  Cancer Metabolism and Immunology
2:00 - 3:00 P.M.  Genome Instability and Cancer Genetics
3:00 - 4:00 P.M.  Cancer Pharmacology

1:00 - 3:00 P.M.  Focus Session B (Multi-Purpose Room B)
1:00 – 2:00 P.M.  Clinical Investigations and Precision Therapeutics
2:00 - 3:00 P.M.  Cancer Prevention and Control

3:00 - 4:30 P.M.  Clinical Trials in Progress Poster Session –Authors Present (Main Lounge)

4:30 P.M.  End of Program
Co-Chairs: Yanxiang (Jessie) Guo, PhD, Associate Professor of Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Danelle Davenport, MSc, PhD, Associate Professor of Molecular Biology, Princeton University, Princeton, NJ

(A1) IDENTIFICATION OF ZBTB24 AS A NOVEL TUMOR SUPPRESSOR IN HEMATOLOGICAL MALIGNANCIES
Rongrong Li1, Namratha Sheshadri1, Jianliang Shen1, Kevin Lu2, Zhiyuan Shen2, Wei-Xing Zong1,2
1Department of Chemical Biology, Ernest Mario School of Pharmacy, Piscataway, NJ
2Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

(A2) CYCLIN C SUPPRESSES PANCREATIC INTERDUCTAL NEOPLASIA AND NEUROENDOCRINE NEOPLASIA PROGRESSION IN A MURINE KRAS MODEL
Kathy Qi Cai1, Sara Hanley2, David C. Stieg2, Andre-Klein Santos4, Kerry S. Campbell1, Randy Strich2
1Institute for Cancer Research, Fox Chase Cancer Center, Philadelphia, PA
2Department of Molecular Biology, Graduate School of Biological Sciences, Rowan University School of Osteopathic Medicine, Stratford, NJ

(A3) SOX9 PROMOTES TUMORIGENESIS IN THE KRASG12D LUNG CANCER MOUSE MODEL THROUGH INCREASING CANCER CELL PROLIFERATION AND SUPPRESSING T CELL FUNCTION
Hua Zhong, Gregory Riedlinger, Jessie Yanxiang Guo, Hatem Sabaawy, Sharon Pine
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

(A4) ARGININE METABOLISM CONFERS METABOLIC VULNERABILITY IN PDAC
Junrong Yan1, Sara Maimouni1,2, Heineken Queen Daguplo1, Jianliang Shen1, Eric Chiles2, Luke Torre-Healy3, Yun Jae Yoo3, Xiaoxuan Lu1, Costas Lyssiotis4, He Wang5, Richard Moffitt3, Xiaoyang Su2, Wei-Xing Zong1,2
1Department of Chemical Biology, Ernest Mario School of Pharmacy, Piscataway, NJ
2Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
3Department of Biomedical Informatics, Stony Brook University, Stony Brook, NY
4Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, MI
5Department of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ

(A5) CPT1A-MEDIATED REGULATION OF ENDOCRINE THERAPY RESISTANCE IN ER+ BREAST CANCER
Shaimaa Hussein1,2, Michael L. Gatza1,2, and Shridar Ganesan1,3
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
2Department of Radiation Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
3Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
Co-Chairs: Wenwei Hu, PhD, Professor of Radiation Oncology, Rutgers Robert Wood Johnson Medical School, Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
Benjamin Raphael, PhD, Professor, Department of Computer Science, Princeton University, Princeton NJ

(A6) DELINEATING DYNAMIC CELL STATE HETEROGENEITY IN BLADDER CANCER
Antara Biswas, Subhajyoti De
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

(A7) EPIGENETIC REGULATION OF BREAST CANCER DORMANCY
Alejandra I. Ferrer1,2, Garima Sinha1,2, Oleta Sandiford1, Pranela Rameshwar2
1School of Graduate Studies, Rutgers, The State University of New Jersey, Newark, NJ
2Department of Medicine, Rutgers, The State University of New Jersey, Newark, NJ

(A8) REGULATION OF THE G2/M CELL CYCLE CHECKPOINT BY BRCA1
Yanira González-Rodríguez1, Samuel F. Bunting2
1Graduate PhD Program in Microbiology and Molecular Genetics, Rutgers, The State University of New Jersey, New Brunswick, NJ
2Department of Molecular Biology and Biochemistry, Rutgers The State University of New Jersey, New Brunswick, NJ

(A9) GENOMIC MARKERS OF RESPONSE TO NEOADJUVANT CARBOPLATIN AND LIPOSOMAL DOXORUBICIN TREATMENT IN TRIPLE NEGATIVE BREAST CANCER
Xiaoju Hu, Nancy Chan, Gregory Riedlinger, Seema Husain, Deborah Toppmeyer, Subhajyoti De, Shridar Ganesan
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

(A10) IDENTIFYING DNA SEQUENCE MOTIFS DISTINCTIVE TO COMMON FRAGILE SITES: A COMPREHENSIVE SURVEY OF REPETITIVE PATTERNS AND THEIR RELATIONSHIP TO GENOMIC INSTABILITY
Nahed Jalloul, Hossein Khiabanian, Advaita Madireddy
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
(A11) COMBINATORIAL TREATMENT WITH INHIBITORS AGAINST GLUTAMATERGIC SIGNALING AND IMMUNE-CHECKPOINT, RESULTED IN A REDUCTION OF TUMOR GROWTH, AND IMPROVED SURVIVAL IN A SPONTANEOUS MELANOMA MOUSE MODEL
Kevinn Eddy1,2, Christina Marinaro1, Maryam Rasheed1, Mohamad N. Eddin1, Joseph Campagnolo1, Raj Shah1, Kajal Gupta2, Anna Chaly6 Katie B. Freeman6, Jeffrey C. Pelletier6, Allen B. Reitz6, Andrew Zloza5, Suzie Chen1,2,3,4
1Susan Lehman Cullman Laboratory for Cancer Research, Rutgers, The State University of New Jersey, Piscataway, NJ
2Graduate Program in Cellular and Molecular Pharmacology, Rutgers, The State University of New Jersey, Piscataway, NJ
3Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
4Environmental & Occupational Health Sciences Institute, Rutgers, The State University of New Jersey, Piscataway, NJ
5Rush University Medical Center, Chicago, IL
6Fox Chase Chemical Diversity Center, Inc., King of Prussia, PA

(A12) CAFFEINE PREVENTS CISPLATIN-INDUCED COGNITIVE DYSFUNCTION IN MICE
Alfredo A. Oliveros1,2, Marwan Mostafa1, Ivan Loncar1, Ki-Hyun Yoo1,2, Ana M. Corujo1, Mi-Hyeon Jang1,2
1Neurosurgery Department, Rutgers Robert Wood Johnson Medical School, Piscataway, NJ
2Department of Neurological Surgery, Mayo Clinic College of Medicine, Rochester MN

(A13) DEVELOPMENT OF A BISPECIFIC ANTIBODY FOR NATURAL KILLER CELL-BASED IMMUNOTHERAPY OF HER2+ OVARIAN CANCER
Shahryar K. Nikhhoi, Arash Hatefi
Department of Pharmaceutics, Rutgers, The State University of New Jersey, Piscataway, NJ

(A14) MTOR REGULATES ARID1A DEGRADATION AND CHROMATIN REMODELING IN TUMORIGENESIS AND ANTI-CANCER THERAPY
Tinghan Zhao1, Shanshan Zhang1, Shuyang Liu1,2, Jian Cao1,3, Stephen K. Burley1,4, X.F. Steven Zheng1,5
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
2School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ
3Department of Medicine, Rutgers, The State University of New Jersey, Piscataway, NJ
4Institute for Quantitative Biomedicine, Rutgers, The State University of New Jersey, Piscataway, NJ
5Department of Pharmacology, Rutgers, The State University of New Jersey, Piscataway, NJ

(A15) SIGMA 1 RECEPTOR ANTAGONISTS AS THERAPEUTICS FOR CHEMOTHERAPY-INDUCED PAIN
Youyi Peng1 and William J. Welsh1,2
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
2Rutgers Robert Wood Johnson Medical School, Piscataway, NJ
(B1) EXPLORING THE INTERPLAY OF GENOMIC REARRANGEMENTS, HOST FACTORS THAT IMPACT CANCER DISPARITIES, AND RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN BLACK WOMEN WITH TRIPLE NEGATIVE BREAST CANCER
Coral Omene¹, Gregory Riedlinger², Yaqun Wang³, Ying Chen⁴, Adana A.M. Llanos⁵, Elisa V. Bandera¹,³, Shridhar Ganesan¹
¹Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
²Division of Translational Pathology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
³Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
⁴Division of Medical Informatics, Department of Pathology & Laboratory Medicine, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
⁵Department of Epidemiology, Mailman School of Public Health and Columbia University Irving Medical Center, New York, NY

(B2) THE LANDSCAPE OF GENETIC ALTERATIONS BASED ON TP53 STATUS IN PATIENTS WITH PANCREATIC ADENOCAncER AND ITS PROGNOSTIC SIGNIFICANCE
Jongmyung Kim, Huzaifa Piperdi, Salma K. Jabbour, Matthew P. Deek
Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

(B3) NEOADJUVANT CHEMOTHERAPY IN OVARIAN CANCER: RACIAL DISPARITIES IN USE AND SURVIVAL OUTCOMES
Saber A. Amin¹, Soko Setoguchi², Jaya M. Satagopan³, Alexandre Buckley de Meritens⁴, Elisa V. Bandera¹
¹Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
²Department of Medicine, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
³Department of Biostatistics and Epidemiology, Rutgers School of Public Health, Piscataway, NJ
⁴Department of OB/GYN and Reproductive Sciences, Division of Gynecologic Oncology, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

(B4) PATHOLOGIC GLEASON GRADE GROUP 1 PROSTATE CANCER IN BLACK MEN – IMPLICATIONS FOR RENAMING IT “NOT CANCER” IN HIGH-RISK POPULATIONS
Courtney Berg, Amjad Alwaal, Robert Weiss, Evan Kovac
Department of Surgery, Division of Urology, Rutgers New Jersey Medical School, Newark, NJ
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

(B5) ASSESSING PRELIMINARY OUTCOMES OF AN ONLINE RESISTANCE EXERCISE PROGRAM AMONG RACIALLY DIVERSE BREAST CANCER SURVIVORS IN NEW JERSEY
Bianca Anuforo¹, Shawna V. Hudson², Sharon L. Manne¹, Angela J. Fong¹
¹Section of Behavioral Sciences, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
²Department of Family Medicine and Community Health, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
(B6) MULTILEVEL FACTORS FOR ADIPOSITY CHANGE IN A POPULATION-BASED PROSPECTIVE STUDY OF BLACK BREAST CANCER SURVIVORS
Qin B1,2, Kim K2, Goldman N3, Rundle AG1, Chanumolu D1, Zeinomar N1,2, Xu B1, Pawlish KS5, Ambrosone CB6, Demissie K7, Hong CC6, Lovasi GS8, Bandera EV1,2
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
2Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ
3Princeton University, Princeton, NJ
4Columbia University, New York, NY
5New Jersey Department of Health, Trenton, NJ
6Roswell Park Comprehensive Cancer Center, Buffalo, NY
7SUNY Downstate Health Sciences University, Brooklyn, NY
8Drexel University, Philadelphia, PA

(Y7) HEAVY DRINKING IN CANCER PATIENTS AND SURVIVORS DURING THE COVID-19 PANDEMIC IN THE US
Yen-Hong Kuo
Office of Research Administration, Hackensack Meridian Health, Neptune, NJ

(B8) RACIAL DISPARITIES IN FEMALE BREAST CANCER SURVIVAL BY MOLECULAR SUBTYPE, AGE, GRADE, AND STAGE
Muhammad Ahmed1, Lisa E. Paddock1,2, Gerald Harris1, Karen Pawlish2, Susan German1, Pamela Agovino2, Antoinette M. Stroup1,2
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
2New Jersey Department of Health, Trenton, NJ

(B9) HPV VACCINE HESITANCY AND INFORMATION NEEDS IN LOW-UPTAKE COMMUNITIES
Racquel E. Kohler1,2, Rachel Wagner1, Katherine Careaga1, Jacqueline Vega1, Rula Btoush3, Kathryn Greene4, Leslie M. Kantor2
1Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
2Rutgers School of Public Health, Rutgers, The State University of New Jersey, Piscataway, NJ
3Rutgers School of Nursing, Rutgers, The State University of New Jersey, New Brunswick, NJ
4Rutgers School of Communication and Information, Rutgers, The State University of New Jersey, New Brunswick, NJ

(B10) PRIMARY CARE PHYSICIAN BELIEFS AND PRACTICES REGARDING LUNG CANCER SCREENING
Steinberg MB, Ramdat C, Jordan HM, Young W, Garthe N, Kota KJ, Musanti R, Kinney AY
Rutgers Center for Tobacco Studies, New Brunswick, NJ
Rutgers Cancer Institute of New Jersey, New Brunswick, NJ